candesartan cilexetil has been researched along with Myocardial Infarction in 13 studies
candesartan cilexetil: a prodrug which is metabolized to an active form candesartan to exert its biological effects
Myocardial Infarction: NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION).
| Excerpt | Relevance | Reference |
|---|---|---|
| " The present study was conducted to examine the combined effects of a chronic ACEI, ramipril, and a chronic Ang II type 1 receptor blocker, TCV116, on rat CHF after myocardial infarction (MI)." | 7.73 | Combined effects of ramipril and angiotensin II receptor blocker TCV116 on rat congestive heart failure after myocardial infarction. ( Huang, YW; Tao, ZW; Xia, Q; Xu, QW, 2005) |
| "The purpose of this study was to examine the cardiac phenotype and remodeling after myocardial infarction and the effect of the angiotensin II type 1 (AT1) receptor antagonist (TCV-116) on the gene expression." | 7.69 | Inhibition by angiotensin II type 1 receptor antagonist of cardiac phenotypic modulation after myocardial infarction. ( Akioka, K; Hanatani, A; Iwao, H; Kim, S; Omura, T; Takeda, T; Takeuchi, K; Teragaki, M; Toda, I; Yoshiyama, M, 1995) |
| " The present study was conducted to examine the combined effects of a chronic ACEI, ramipril, and a chronic Ang II type 1 receptor blocker, TCV116, on rat CHF after myocardial infarction (MI)." | 3.73 | Combined effects of ramipril and angiotensin II receptor blocker TCV116 on rat congestive heart failure after myocardial infarction. ( Huang, YW; Tao, ZW; Xia, Q; Xu, QW, 2005) |
| "Because the effects of an aldosterone receptor antagonist on transcriptional factors and mRNA expression have not been fully examined in myocardial infarction (MI), the present study examined the effects of spironolactone (SPIRO) and candesartan cilexitil (CAN) on activation of activator protein-1 (AP-1), nuclear factor-kappaB (NF-kappaB) and mRNA expression in the non-ischemic myocardium after MI." | 3.72 | Effects of aldosterone receptor antagonist and angiotensin II type I receptor blocker on cardiac transcriptional factors and mRNA expression in rats with myocardial infarction. ( Akioka, K; Iwao, H; Izumi, Y; Kim, S; Matsumoto, R; Nakamura, Y; Omura, T; Takeuchi, K; Yoshikawa, J; Yoshiyama, M, 2004) |
| "To investigate the long-term effects of TCV116 (candesartan cilexetil) on cardiac function changes after myocardial infarction." | 3.72 | [Long-term effects of TCV116 on cardiac function changes after myocardial infarction]. ( Tao, ZW; Wang, Y; Wang, YW, 2004) |
| "The aims were (1) to investigate the effect of hypertention on left ventricular dilatation and haemodynamic alterations following acute myocardial infarction in spontaneously hypertensive rats (SHR) and normotensive rats (WKY); (2) to compare haemodynamic indices between the two groups; (3) to assess whether the angiotensin II type 1 receptor antagonist (AIIA), TCV-116, prevented left ventricular dilatation after myocardial infarction; and (4) to compare the effect of AIIA with that of the angiotensin converting enzyme (ACE) inhibitor, delapril." | 3.69 | An angiotensin II receptor antagonist attenuates left ventricular dilatation after myocardial infarction in the hypertensive rat. ( Nishikimi, T; Takeda, T; Takeuchi, K; Yamagishi, H, 1995) |
| "The purpose of this study was to examine the cardiac phenotype and remodeling after myocardial infarction and the effect of the angiotensin II type 1 (AT1) receptor antagonist (TCV-116) on the gene expression." | 3.69 | Inhibition by angiotensin II type 1 receptor antagonist of cardiac phenotypic modulation after myocardial infarction. ( Akioka, K; Hanatani, A; Iwao, H; Kim, S; Omura, T; Takeda, T; Takeuchi, K; Teragaki, M; Toda, I; Yoshiyama, M, 1995) |
| "To investigate the contribution of the cardiac renin-angiotensin system to ventricular dilatation after myocardial infarction, we examined the effects of 3-week treatments with an angiotensin converting enzyme inhibitor, delapril, and a selective angiotensin II type 1 (AT1) receptor antagonist, TCV-116, on haemodynamics and ventricular angiotensin II contents in myocardial-infarcted rats." | 3.68 | Contribution of cardiac renin-angiotensin system to ventricular remodelling in myocardial-infarcted rats. ( Kim, S; Nishikimi, T; Takeda, T; Takeuchi, K; Yamagishi, H, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (53.85) | 18.2507 |
| 2000's | 6 (46.15) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Matsumoto, R | 2 |
| Yoshiyama, M | 4 |
| Omura, T | 4 |
| Kim, S | 4 |
| Nakamura, Y | 1 |
| Izumi, Y | 2 |
| Akioka, K | 3 |
| Iwao, H | 4 |
| Takeuchi, K | 6 |
| Yoshikawa, J | 3 |
| Tao, ZW | 2 |
| Wang, YW | 1 |
| Wang, Y | 1 |
| Huang, YW | 1 |
| Xia, Q | 1 |
| Xu, QW | 1 |
| Kusuyama, T | 2 |
| Nishiya, D | 1 |
| Enomoto, S | 1 |
| Suzuki, H | 2 |
| Omori, Y | 1 |
| Soda, T | 1 |
| Tsunoda, F | 1 |
| Sato, T | 1 |
| Shoji, M | 1 |
| Iso, Y | 1 |
| Kondo, T | 1 |
| Koba, S | 1 |
| Geshi, E | 1 |
| Katagiri, T | 1 |
| Lange, SA | 1 |
| Wolf, B | 1 |
| Schober, K | 1 |
| Wunderlich, C | 1 |
| Marquetant, R | 1 |
| Weinbrenner, C | 1 |
| Strasser, RH | 1 |
| Nishikimi, T | 2 |
| Yamagishi, H | 2 |
| Takeda, T | 3 |
| Nio, Y | 2 |
| Matsubara, H | 2 |
| Murasawa, S | 2 |
| Kanasaki, M | 1 |
| Inada, M | 2 |
| Hanatani, A | 2 |
| Toda, I | 1 |
| Teragaki, M | 1 |
| Kijima, K | 1 |
| Maruyama, K | 1 |
| Mori, Y | 1 |
| Nishizawa, M | 1 |
| Kumagai, H | 1 |
| Ichikawa, M | 1 |
| Oshima, N | 1 |
| Saruta, T | 1 |
| Nakayama, K | 1 |
13 other studies available for candesartan cilexetil and Myocardial Infarction
| Article | Year |
|---|---|
Effects of aldosterone receptor antagonist and angiotensin II type I receptor blocker on cardiac transcriptional factors and mRNA expression in rats with myocardial infarction.
Topics: Animals; Atrial Natriuretic Factor; Benzimidazoles; Biphenyl Compounds; Collagen Type I; Collagen Ty | 2004 |
[Long-term effects of TCV116 on cardiac function changes after myocardial infarction].
Topics: Angiotensin II Type 2 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Heart Failure; | 2004 |
Combined effects of ramipril and angiotensin II receptor blocker TCV116 on rat congestive heart failure after myocardial infarction.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; Biphenyl Compounds; Blood Pressur | 2005 |
Angiotensin blockade inhibits osteopontin expression in non-infarcted myocardium after myocardial infarction.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Chemokine CCL2 | 2005 |
Inhibitory effect of candesartan cilexetil on left ventricular remodeling after myocardial infarction.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; B | 2006 |
Chronic angiotensin II receptor blockade induces cardioprotection during ischemia by increased PKC-epsilon expression in the mouse heart.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensin-Converting En | 2007 |
An angiotensin II receptor antagonist attenuates left ventricular dilatation after myocardial infarction in the hypertensive rat.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; Biphenyl Compounds; Cardiomyopath | 1995 |
Regulation of gene transcription of angiotensin II receptor subtypes in myocardial infarction.
Topics: Angiotensin Receptor Antagonists; Animals; Base Sequence; Benzimidazoles; Biphenyl Compounds; Blood | 1995 |
Contribution of cardiac renin-angiotensin system to ventricular remodelling in myocardial-infarcted rats.
Topics: Analysis of Variance; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzym | 1993 |
Inhibition by angiotensin II type 1 receptor antagonist of cardiac phenotypic modulation after myocardial infarction.
Topics: Actins; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Atrial N | 1995 |
Regulation of gene transcription of angiotensin II receptor subtypes in the heart.
Topics: Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Body | 1996 |
Improvement in baroreflex function by an oral angiotensin receptor antagonist in rats with myocardial infarction.
Topics: Administration, Oral; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Baroreflex | 1997 |
Angiotensin II type 1-receptor antagonist candesartan cilexitil prevents left ventricular dysfunction in myocardial infarcted rats.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Atrial Natriuretic Factor; Benzi | 1998 |